Table 1 Demographic characteristics and oncological and functional outcomes of the study group
From: The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer
Variable | Value |
|---|---|
Patients (n) | 27 |
Age (years, median, range) | 71 (48–80) |
Initial PSA value (ng/ml, median, range) | 6.2 (4–23.6) |
Initial volume of prostate before CA (cc, median, range) | 29 (15–53) |
Volume of prostate after repeat CA (cc, median, range) | 18 (10–48) |
Gleason score at initial diagnosis | |
6 (n %) | 5 (19) |
7 (n %) | 13 (48) |
8 or 9 (n %) | 9 (33) |
Initial clinical stage before first CA | |
T1c (n %) | 15 (55) |
T2 (n %) | 11 (41) |
T3 (n %) | 1 (4) |
Initial therapy before first CA | |
HT (n %) | 6 (22) |
HT and either RT or BT (n %) | 5 (19) |
RT (n %) | 1 (4) |
Interval between first CA and positive biopsy (median, months) | 23 (6–63) |
PSA value at positive biopsy after first CA (median, ng/ml) | 2.7 (0.2–7.8) |
Postoperative complications of repeat CA (n %) | |
Continence (no pad usage) | 24/26 (92) |
Stricture | 1/26 (3.84) |
PSA value at last follow-upa | |
Median value among patients with detectable PSA (ng/ml) | 0.8 (0.2–50) |
Patients with undetectable PSA (n %) | 5/26a (19) |
Patients with PSA value <0.5 ng/ml (n %) | 13/26 (50) |
Patients with PSA value ≥0.5 ng/ml (n %) | 8/26 (31 %) |